Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience
Explore this paper's citation graph
Summary
In this real-life study, SOR significantly increased the survival rate by 1 year in patients with advanced HCC regardless of BCLC staging and CP score.
- Type
- article
- Published
- 2018-07-13
- Cited by
- 28
- References
- 26
- OpenAlex
- https://openalex.org/W2883746685
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:51628297
Keywords
Medicine, Sorafenib, Hepatocellular carcinoma, Internal medicine, Oncology
References
- Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score
- Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma.
- Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil
- Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months: A 15-Year Prospective Study
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
- Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
- Management of hepatocellular carcinoma: An update
- Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
- Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
- Hepatocellular carcinoma: a review
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
- Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
- Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.
- Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil.
- The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib.
- Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
- Use of inhibitors of the renin angiotensin system is associated with longer survival in patients with hepatocellular carcinoma
- On‐target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi‐centre, prospective study
Cited by
- Treatment strategies for locally advanced hepatocellular carcinoma.
- Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment
- Anaphylaxis preceded by erythema multiforme with sorafenib: First case report.
- Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer
- Roles and Regulation of Long non-coding RNAs in Hepatocellular Carcinoma.
- Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population
- Hepatic flow is an intraoperative predictor of early allograft dysfunction in whole-graft deceased donor liver transplantation: An observational cohort study
- Mouse Models for Immunotherapy in Hepatocellular Carcinoma
- Sequential drug delivery for liver diseases.
- Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells
- Author Correction: Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data
- Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
- Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
- BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4
- Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: an update.
- Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.
- Treating Advanced Hepatocellular Carcinoma with Sorafenib: A 10-Year Single Center Experience
- Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data
- Stearoyl-CoA desaturase 1 as a therapeutic target for cancer: a focus on hepatocellular carcinoma
- Galactosylated Polymer/Gold Nanorods Nanocomposites for Sustained and Pulsed Chemo-Photothermal Treatments of Hepatocarcinoma
Related papers
- Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
- Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma
- Heat Shock Protein 27 Expression Levels are associated with the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib
- High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Treatment options after sorafenib failure in patients with hepatocellular carcinoma
- Data from High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma
- Sorafenib in hepatocellular carcinoma.
- Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
- Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.